Evaluation of Efficacy of House Dust Mite Immunotherapy in Children With Bronchial Asthma

Phase 4

• Conditions: Asthma
• Interventions: Biological: Novo Helisen Depot, Phostal

• Registration Number: NCT00496574
• Lead Sponsor: Medical University of Lodz

Brief Summary

The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, bronchial hyperreactivity with methacholine, and presence and type of allergy after three years of SIT in children with asthma.

Detailed Description

According to Global Initiative for Asthma treatment of asthma is based on avoidance of allergens, pharmacological treatment, and specific immunotherapy.

The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, bronchial hyperreactivity with methacholine, and presence and type of allergy after three years of SIT in children with asthma.

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2007-07-03
• Study First Submitted QC: 2007-07-03
• Study First Posted: 2007-07-04
• Status Verified: 2013-02
• Last Update Submitted: 2013-02-06
• Last Update Posted: 2013-02-07
• Primary Completion: 2013-11
• Study Completion: 2013-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• patients allergic to house dust mites
• patients with moderate bronchial asthma
• patients with controlled asthma
• patients who were qualified for immunotherapy and gave written informed consent for immunotherapy (active treatment group)
• patients who were qualified for immunotherapy and did not agree with this kind of treatment - did not give written informed consent for immunotherapy (control group)

Read More

Exclusion Criteria

• patients allergic for other perennial and seasonal allergens
• patients with other chronic diseases that either put the patient at risk when participating in the study or could influence the results of the study or the patient's ability to participate in the study as judged by the investigator
• medications that resulted in patient exclusion included:anti-parasites or oral corticosteroids within 6 months before the first visit.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Novo Helisen Depot, Phostal	-

Primary Outcome Measures

Name	Time	Method
clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function	baseline (first visit), 12 months (second visit), 24 months (third visit), 36 months (fourth visit)

Secondary Outcome Measures

Name	Time	Method
bronchial hyperreactivity with methacholine, and presence and type of allergy after tree years of SIT in children with asthma.	after 36 months (fourth visit)

Trial Locations

Locations (1)

Department of Pediatrics and Allergy, Medical University of Lodz, Poland; 🇵🇱 Lodz, Poland